Dr George Vassiliou

George's research seeks to understand the genetic pathways involved in the pathogenesis of haematological cancers and help develop targeted anti-leukaemic therapies.

George is a Wellcome Trust Senior Clinical Fellow and heads the Haematological Cancer Genetics Group. His group is studying the pathogenesis and treatment of haematological malignancies with a particular focus on acute myeloid leukaemia and multiple myeloma. He is also a Consultant Haematologist at Addenbrooke's Hospital in Cambridge where he treats patients with these diseases.

Selected Publications

• Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice.

  Vassiliou GS, Cooper JL, Rad R, Li J, Rice S, Uren A, Rad L, Ellis P, Andrews R, Banerjee R, Grove C, Wang W, Liu P, Wright P, Arends M and Bradley A

  Nature genetics 2011;43;5;470-5

  PUBMED: 21441929; PMC: 3084174; DOI: 10.1038/ng.796

• PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice.

  Rad R, Rad L, Wang W, Cadinanos J, Vassiliou G, Rice S, Campos LS, Yusa K, Banerjee R, Li MA, de la Rosa J, Strong A, Lu D, Ellis P, Conte N, Yang FT, Liu P and Bradley A

  Science (New York, N.Y.) 2010;330;6007;1104-7

  PUBMED: 20947725; DOI: 10.1126/science.1193004

• The use of DNA transposons for cancer gene discovery in mice.

  Vassiliou G, Rad R and Bradley A

  Methods in enzymology 2010;477;91-106

  PUBMED: 20699138; DOI: 10.1016/S0076-6879(10)77006-3

• New approaches for modelling sporadic genetic disease in the mouse.

  Fisher EM, Lana-Elola E, Watson SD, Vassiliou G and Tybulewicz VL

  Disease models & mechanisms 2009;2;9-10;446-53

  PUBMED: 19726804; PMC: 2737055; DOI: 10.1242/dmm.001644

• An acquired translocation in JAK2 Val617Phe-negative essential thrombocythemia associated with autosomal spread of X-inactivation.

  Vassiliou GS, Campbell PJ, Li J, Roberts I, Swanton S, Huntly BJ, Fourouclas N, Baxter EJ, Munro LR, Culligan DA, Scott LM and Green AR

  Haematologica 2006;91;8;1100-4

  PUBMED: 16885051

• Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

  Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR, United Kingdom Myeloproliferative Disorders Study Group, Medical Research Council Adult Leukaemia Working Party and Australasian Leukaemia and Lymphoma Group

  Lancet 2005;366;9501;1945-53

  PUBMED: 16325696; DOI: 10.1016/S0140-6736(05)67785-9

• L3mbtl, the mouse orthologue of the imprinted L3MBTL, displays a complex pattern of alternative splicing and escapes genomic imprinting.

  Li J, Bench AJ, Piltz S, Vassiliou G, Baxter EJ, Ferguson-Smith AC and Green AR

  Genomics 2005;86;4;489-94

  PUBMED: 16081246; DOI: 10.1016/j.ygeno.2005.06.012

• Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

  Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR and Cancer Genome Project

  Lancet 2005;365;9464;1054-61

  PUBMED: 15781101; DOI: 10.1016/S0140-6736(05)71142-9

• Imprinting of the human L3MBTL gene, a polycomb family member located in a region of chromosome 20 deleted in human myeloid malignancies.

  Li J, Bench AJ, Vassiliou GS, Fourouclas N, Ferguson-Smith AC and Green AR

  Proceedings of the National Academy of Sciences of the United States of America 2004;101;19;7341-6

  PUBMED: 15123827; PMC: 409920; DOI: 10.1073/pnas.0308195101